ACP-211 is developed by ACADIA Pharmaceuticals Inc..

What are the side effects of ACP-211?

Common side effects include Headache, Nausea, Dizziness.

Last reviewed 2026-04-23 · How we verify

ACP-211

ACADIA Pharmaceuticals Inc. · Phase 2 active Small molecule

ACP-211 is a selective histamine H3 receptor inverse agonist.

ACP-211 is a selective histamine H3 receptor inverse agonist. Used for Treatment of excessive daytime sleepiness in patients with narcolepsy.

At a glance

Generic name	ACP-211
Sponsor	ACADIA Pharmaceuticals Inc.
Drug class	histamine H3 receptor inverse agonist
Target	histamine H3 receptor
Modality	Small molecule
Therapeutic area	Neurology
Phase	Phase 2

Mechanism of action

ACP-211 works by binding to the histamine H3 receptor, which is involved in regulating sleep-wake cycles and arousal. By acting as an inverse agonist, ACP-211 can increase the activity of histamine neurons, leading to increased alertness and wakefulness.

Approved indications

Treatment of excessive daytime sleepiness in patients with narcolepsy

Common side effects

Headache
Nausea
Dizziness

Key clinical trials

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results